Zacks Investment Research downgraded shares of Xenetic Biosciences, Inc. (NASDAQ:XBIO) from a buy rating to a hold rating in a report published on Wednesday.

According to Zacks, “Xenetic Biosciences Inc. is a biopharmaceutical company. It develops biologic drugs, oncology therapeutics and vaccinations. The Company’s proprietary drug technology platforms include PolyXen (R) for the development of next generation biologic drugs and OncoHist (R) for the development of oncology drugs focused on orphan indications. Xenetic Biosciences Inc. based in United States. “

Xenetic Biosciences (XBIO) opened at 2.51 on Wednesday. Xenetic Biosciences has a 52 week low of $2.30 and a 52 week high of $5.75. The company’s market capitalization is $21.88 million. The stock has a 50 day moving average price of $2.59 and a 200-day moving average price of $3.33.

Xenetic Biosciences (NASDAQ:XBIO) last announced its earnings results on Monday, August 14th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by ($0.13). On average, equities analysts predict that Xenetic Biosciences will post ($0.89) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Xenetic Biosciences, Inc. (XBIO) Downgraded by Zacks Investment Research” was reported by Daily Political and is owned by of Daily Political. If you are reading this story on another publication, it was illegally stolen and reposted in violation of international copyright and trademark law. The correct version of this story can be viewed at

Xenetic Biosciences Company Profile

Xenetic Biosciences, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the research and development of certain pharmaceutical products for use in humans that includes the use of the Company’s platform technologies that enables the creation of drug therapies primarily for orphan indications.

Get a free copy of the Zacks research report on Xenetic Biosciences (XBIO)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Xenetic Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenetic Biosciences Inc. and related companies with's FREE daily email newsletter.